GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Tax Provision

GRFS (Grifols) Tax Provision : $-220 Mil (TTM As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Grifols Tax Provision?

Grifols's tax provision for the three months ended in Sep. 2024 was $-42 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $-220 Mil.

Grifols Tax Provision Historical Data

The historical data trend for Grifols's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Tax Provision Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -206.37 -96.19 -95.46 -47.27 -242.08

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.96 -30.16 -45.44 -41.56 -132.73

Grifols Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-220 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Tax Provision
Comparable Companies
XMAD:ALM XMAD:FAE XMAD:RJF XMAD:LAB LLY OCSE:NOVO B JNJ ABBV XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568
Traded in Other Exchanges
GIKLY:USA GIFOF:USA GIFLF:USA GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany GRF:Austria
Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Website
https://www.grifols.com
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.